The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Xing, L., Dai, Z., Jabbari, A., Cerise, J. E., Higgins, C. A., Gong, W., de Jong, A., Harel, S., DeStefano, G. M., Rothman, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3645 · Cited by 987
Alopecia areata investigational assessment guidelines–Part II
Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., Duvic, M., King, L. E., McMichael, A. J., Randall, V. A., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.09.032 · Cited by 798
Incidence of Alopecia Areata in Olmsted County, Minnesota, 1975 Through 1989
Safavi, K. H., Muller, S. A., Suman, V. J., Moshell, A. N., & Melton, L. J. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.7.628 · Cited by 528
Fleischmann, R., Cutolo, M., Genovese, M. C., Lee, E. B., Kanik, K. S., Sadis, S., Connell, C. A., Gruben, D., Krishnaswami, S., Wallenstein, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33383 · Cited by 376
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89776 · Cited by 355
Self-citationWollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
Alopecia areata investigational assessment guidelines*
Olsen, E., Hordinsky, M., McDonald-Hull, S., Price, V., Roberts, J., Shapiro, J., & Stenn, K. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70195-7 · Cited by 251
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.015 · Cited by 233
Craiglow, B. G., & King, B. A. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.260 · Cited by 223
Self-citationLifetime prevalence of psychiatric disorders in patients with alopecia areata
Colón, E. A., Popkin, M. K., Callies, A. L., Dessert, N. J., & Hordinsky, M. K. (1991) · Comprehensive Psychiatry · doi:10.1016/0010-440x(91)90045-e · Cited by 184
Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review
Liu, L. Y., King, B. A., & Craiglow, B. G. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.035 · Cited by 176
Self-citationOtberg, N., Finner, A. M., & Shapiro, J. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.004 · Cited by 174
Interventions for alopecia areata
Delamere, F. M., Sladden, M. J., Dobbins, H. M., & Leonardi-Bee, J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004413.pub2 · Cited by 170
Topical Ruxolitinib for the Treatment of Alopecia Universalis
Craiglow, B. G., Tavares, D., & King, B. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.4445 · Cited by 120
Self-citation
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Pratt, C. H., King, L. E., Messenger, A. G., Christiano, A. M., & Sundberg, J. P. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.11 · Cited by 787
JAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Self-citationErratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 394
Metadata
- Authors
- Liu, L. Y., Craiglow, B. G., Dai, F., & King, B. A.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 76
- Issue
- 1
- Pages
- 22-28
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2548580472
- Cited by
- 349
- References
- 15
- FWCI
- 49.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.